IM Cannabis (NASDAQ:IMCC) Rating Lowered to “Strong Sell” at Wall Street Zen

IM Cannabis (NASDAQ:IMCC) was downgraded by research analysts at Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IM Cannabis in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

IM Cannabis Price Performance

IMCC opened at $1.58 on Friday. The company’s 50-day moving average is $2.84 and its 200 day moving average is $5.92. IM Cannabis has a fifty-two week low of $1.55 and a fifty-two week high of $77.10. The firm has a market capitalization of $327,060.00, a P/E ratio of -0.03 and a beta of 2.21.

IM Cannabis (NASDAQ:IMCC) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter. The company had revenue of $5.34 million for the quarter.

IM Cannabis Company Profile

IM Cannabis Corp. is a medical cannabis company focused on the cultivation, importation, distribution and sale of cannabis products. The company markets products under the IMC brand and serves patients through regulated medical cannabis channels.

IM Cannabis operates primarily in Israel and Germany. In Israel, the company’s activities include supplying medical cannabis products through pharmacies and other authorized distribution channels. In Germany, it participates in the medical cannabis market through the importation and distribution of pharmaceutical-grade products.

The company was established in 2018 and has developed its business through subsidiaries and strategic partnerships in its target markets.